Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

(2014) C. Saura et al.   CLINICAL CANCER RESEARCH

Basal/HER2 breast carcinomas

(2013) Begoña Martin-Castillo et al.   CELL CYCLE

Are Breast Cancer Molecular Classes Predictive of Survival in Patients with Long Follow-Up?

(2013) Danae Pracella et al.   DISEASE MARKERS

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

(2013) Aron Goldhirsch et al.   LANCET

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

(2013) Xiaosong Chen et al.   MOLECULAR CANCER RESEARCH

Stromal cells in tumor microenvironment and breast cancer

(2012) Yan Mao et al.   CANCER AND METASTASIS REVIEWS

CCL2 Mediates Cross-talk between Cancer Cells and Stromal Fibroblasts That Regulates Breast Cancer Stem Cells

(2012) A. Tsuyada et al.   CANCER RESEARCH

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

(2012) Gary Hudes et al.   INVESTIGATIONAL NEW DRUGS

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population

(2012) Hasan Korkaya et al.   MOLECULAR CELL

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

(2012) Yu Sun et al.   NATURE MEDICINE

The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin

(2011) Osvaldo Pontiggia et al.   BREAST CANCER RESEARCH AND TREATMENT

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

(2011) Jermaine Coward et al.   CLINICAL CANCER RESEARCH

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

(2011) Lauren L.C. Marotta et al.   JOURNAL OF CLINICAL INVESTIGATION

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM

(2010) Y Wang et al.   ONCOGENE

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

Stromal gene expression predicts clinical outcome in breast cancer

(2008) Greg Finak et al.   NATURE MEDICINE